Its common adverse events include anemia, leukopenia, pancytopenia, nausea, hyperbilirubinemia, hypophosphatemia, and anorexia.1063 A phase I trial of MK-8242 in patients with refractory/recurrent AML has been completed.1064 Furthermore, Milademetan (DS3032b) is an orally active MDM2 inhibitor by disrupting the MDM2-p53 interaction.1065 A phase I study of milademetan in combination with low-dose cytarabine with or without venetoclax for the treatment of AML has been completed, and has revealed modest therapeutic responses with recognizable gastrointestinal toxicity.1065. This evidence concerns the gene MDM2 and anemia (phenotype).